Fidelity Investments
TVRD

Fidelity Investments’s Tvardi Therapeutics TVRD Stock Holding History

Fidelity Investments’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8K Sell
5,278
-1,321
-20% -$5.18K ﹤0.01% 4584
2025
Q4 		$28.4K Sell
6,599
-75,622
-92% -$678K ﹤0.01% 4329
2025
Q3 		$3.2M Buy
82,221
+82,216
+1,644,320% +$2.34M ﹤0.01% 2383
2025
Q2 		$117 Buy
5
+4
+400% +$95 ﹤0.01% 5129
2025
Q1 		$20 Sell
1
-6,467
-100% -$97.6K ﹤0.01% 5227
2024
Q4 		$119K Buy
6,468
+626
+11% +$6.81K ﹤0.01% 3473
2024
Q3 		$64.8K Buy
5,842
+911
+18% +$10.7K ﹤0.01% 3673
2024
Q2 		$45.8K Buy
4,931
+427
+9% +$10.2K ﹤0.01% 3659
2024
Q1 		$148K Buy
4,504
+134
+3% +$3.48K ﹤0.01% 3139
2023
Q4 		$117K Sell
4,370
-162
-4% -$6.71K ﹤0.01% 3155
2023
Q3 		$274K Buy
4,532
+301
+7% +$28.2K ﹤0.01% 2783
2023
Q2 		$431K Buy
4,231
+4,187
+9,516% +$577K ﹤0.01% 2701
2023
Q1 		$7.81K Sell
44
-8
-15% -$2.68K ﹤0.01% 4229
2022
Q4 		$20.2K Buy
52
+34
+189% +$12.9K ﹤0.01% 3777
2022
Q3 		$6K Sell
18
-27
-60% -$9.78K ﹤0.01% 4277
2022
Q2 		$15K Sell
45
-1,606
-97% -$563K ﹤0.01% 3985
2022
Q1 		$722K Buy
1,651
+1,650
+165,000% +$677K ﹤0.01% 2869
2021
Q4 		$1K Sell
1
-6
-86% -$3.02K ﹤0.01% 4223
2021
Q3 		$4K Hold
7
– – ﹤0.01% 3877
2021
Q2 		$4K Buy
7
+5
+250% +$3.17K ﹤0.01% 3804
2021
Q1 		$2K Buy
2
+1
+100% +$685 ﹤0.01% 3766
2020
Q4 		$1K Buy
+1
New +$524 ﹤0.01% 3746
2019
Q4 		– Sell
-64
Closed -$42K – 4337
2019
Q3 		$42K Sell
64
-15,930
-100% -$13.2M ﹤0.01% 2903
2019
Q2 		$12.4M Hold
15,994
– – ﹤0.01% 1812
2019
Q1 		$11.3M Hold
15,994
– – ﹤0.01% 1816
2018
Q4 		$7.49M Sell
15,994
-1,507
-9% -$972K ﹤0.01% 1898
2018
Q3 		$15.1M Sell
17,501
-1,714
-9% -$1.24M ﹤0.01% 1803
2018
Q2 		$13.2M Hold
19,215
– – ﹤0.01% 1858
2018
Q1 		$8.56M Sell
19,215
-5,108
-21% -$2.48M ﹤0.01% 2000
2017
Q4 		$10.7M Sell
24,323
-7,908
-25% -$3.61M ﹤0.01% 1934
2017
Q3 		$15.9M Sell
32,231
-1,069
-3% -$535K ﹤0.01% 1775
2017
Q2 		$18.4M Buy
33,300
+7,223
+28% +$4.58M ﹤0.01% 1709
2017
Q1 		$17.3M Buy
26,077
+23,549
+932% +$12.6M ﹤0.01% 1747
2016
Q4 		$845K Buy
+2,528
New +$811K ﹤0.01% 2490
2016
Q2 		– Sell
-44,229
Closed -$9.9M – 2708
2016
Q1 		$9.9M Sell
44,229
-63,438
-59% -$18.9M ﹤0.01% 1969
2015
Q4 		$65.3M Sell
107,667
-656
-0.6% -$360K 0.01% 1155
2015
Q3 		$55.7M Buy
108,323
+76,114
+236% +$51M 0.01% 1203
2015
Q2 		$14.1M Hold
32,209
– – ﹤0.01% 1883
2015
Q1 		$11.7M Hold
32,209
– – ﹤0.01% 1945
2014
Q4 		$11.6M Sell
32,209
-3,580
-10% -$1.15M ﹤0.01% 1946
2014
Q3 		$10.8M Sell
35,789
-7,907
-18% -$3.25M ﹤0.01% 1979
2014
Q2 		$26.8M Buy
43,696
+3,872
+10% +$2.08M ﹤0.01% 1650
2014
Q1 		$26.7M Buy
+39,824
New +$23.6M ﹤0.01% 1633

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Fidelity Investments's TVRD Position: Q1 2026 in Review

Fidelity Investments reduced its Tvardi Therapeutics (TVRD) stake by 20% in Q1 2026, selling an estimated $5.18K and leaving 5,278 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4584.

Fidelity Investments first reported a position in TVRD in Q1 2014 and has held it in 43 quarters since. The position peaked at $65.3M in Q4 2015. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Fidelity Investments held 5,278 shares of Tvardi Therapeutics worth $16.8K as of Q1 2026.
  • Fidelity Investments sold 1,321 Tvardi Therapeutics shares in Q1 2026, an estimated $5.18K.
  • Tvardi Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4584 holding.
  • Fidelity Investments first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 43 quarters since.
  • Fidelity Investments's Tvardi Therapeutics position peaked at $65.3M in Q4 2015.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.